

---

# Index

## A

- Acetylcholine (Ach), 201–202
- Acute cutaneous inflammation
  - pathways, 198
  - pharmacology, 197–198
- Acute pain, 148–149. *See also*
  - Endocannabinoid (EC) system
- Adenosine, 197
- Adenosine monophosphate-activated protein kinase (AMPK), 22
- $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, 215
- Amygdala, 7, 11
  - circuitry, 262–264
  - LA-BLA and CeA, 264
  - pharmacology of
    - amino acid neurotransmitters, 266
    - CGRP, 274–275
    - CRF, 275–277
    - GABA, 272–273
    - ionotropic glutamate receptors, 266–268
    - metabotropic glutamate receptors, 268–272
    - NPS, 277–278
  - plasticity
    - electrophysiological studies, 264
    - excitatory transmission, 265–266
    - neuronal activity changes, 265
    - output, 26
- Analgesics
  - new Nav1.7 channel, 52–53
  - postsurgery pain, 30
  - sex differences in, 227–228
- Anandamide (AEA), 124, 125
- Anterolateral tract (ALT), 173
- 2-arachidonoyl glycerol (2-AG), 124, 125

- Astrocytes, 210–211
  - classification, 148
  - origin, 147
  - physiological conditions, 148
- ATP, 219–220
- Atypical PKC (aPKC)
  - intrathecal injection of, 25, 27
  - LTP, 24, 25
  - pep2m, 26
  - PKM $\zeta$ , 24
  - role of, 25
  - ZIP, 26

## B

- Blood–brain barrier (BBB)
  - endothelial cells, 211
  - permeable pharmacotherapies, 229
- Brain derived neurotrophic factor (BDNF), 24, 26–27

## C

- Calcitonin gene-related peptide (CGRP), 173
  - antinociceptive effects of, 275
  - electrophysiological data, 274
  - functional receptors, 274
  - during migraine attacks, 226
  - stereotaxic administration of, 274–275
- Cannabinoids
  - CB<sub>1</sub> receptor, 123–124
  - definition, 121
- Cannabinoid type 2 receptor (CB<sub>2</sub> receptor)
  - activation of, 124
  - modulation of, 130
  - role of, 128–129
- Cardiovascular system, 243–244
- Chemokine ligand 2 (CCL2), 217

- Chemokine ligand 5 (CCL5), 223
- Central immune cell  
 non-stereoselective activation, 213  
 signalling, 208  
 synergy, 211
- Central nervous system (CNS)  
 astrocytes, 210–211  
 CB<sub>1</sub> receptor, 123  
 cytokines, 213–215  
 microglia, 210 (*see also* Microglia)  
 non-neuronal cell intracellular signalling in,  
 209
- Central sensitization  
 definition, 6  
 in chronic pain  
 animal studies on, 81  
 conditions, 80–81  
 extraterritorial manifestations of, 82–83  
 local ipsilateral, 82  
 treatment of, 80  
 widespread manifestations of, 83–84
- itch (*see also* Itch)  
 exact mechanisms and roles of, 294  
 mechanical hyperalgesia, 293  
 pruriceptors ongoing activity, 294  
 punctate hyperalgesia, 293
- pain, 293–295
- Quantitative sensory testing (QST) for  
 assessment methods, 84  
 descending pain modulation, 90–91  
 different protocols, 84  
 localized vs. general hyperalgesia  
 problem, 85–86  
 offset analgesia, 91–92  
 provoked facilitation, 86, 87  
 referred pain, 92–93  
 reflex receptive fields, 89–90  
 spatial summation, 89  
 temporal summation and aftersensation,  
 86–88
- cGMP signaling, 108–110
- Chemokines, 216–217
- Cholecystokinin (CCK), 217–219
- Chronic constriction injury (CCI), 62, 180
- Chronic inflammation, 295–296
- Chronic pain  
 EC in, 128–129  
 spinal cord, in neuropathic and  
 inflammatory pain, 148–149
- c-Jun N-terminal kinase (JNK)  
 in astrocytes, 209  
 phosphorylation of, 158
- Collagen-induced arthritis (CIA), 159
- Corticotropin-releasing factor (CRF)  
 changes of, 276–277  
 effects of, 277  
 electrophysiological studies, 275  
 endogenous receptor activation, 276, 277  
 extrahypothalamic expression of, 275  
 patch-clamp analysis, 276  
 receptor antagonist, 275  
 sources of, 275
- CPEB. *See* Cytoplasmic polyadenylation  
 element-binding protein (CPEB)
- Crosstalk, receptor, 222–225
- Cuff-algometry technology, 89
- Cutaneous mechanical hyperalgesia, 60
- CX3LC1 (Fraktalkine)/R1, 153–154
- C-X-C chemokine receptor 1 (CXCR1), 223
- C-X-C chemokine receptor 2 (CXCR2), 223
- C-X-C chemokine receptor 4 (CXCR4), 224
- CX3C (Fractalkine) receptor-1 (CX3CR1),  
 216, 224
- Cytokine-mediated neuronal excitation,  
 215–216
- Cytokines, 213–215
- Cytoplasmic polyadenylation element-binding  
 protein (CPEB), 23, 24
- D**
- Delayed onset muscle soreness (DOMS),  
 63–65
- Descending pain modulation, 90–91
- Desensitisation, 222, 243
- Diacylglycerol lipase- $\alpha$  (DAGL $\alpha$ ), 125, 127
- Dorsal root ganglia (DRG), 41
- Dorsal root reflex (DRR)  
 glial dependence of, 196–197  
 spinal cord modulation of peripheral  
 inflammation, 193–194
- E**
- Endocannabinoid (EC) system  
 acute pain processing, 127–128  
 CB<sub>2</sub> receptors (*see* Cannabinoid type  
 2 receptor (CB<sub>2</sub> receptor))  
 comparison of classical neurotransmitter  
 systems, 121  
 endogenous ligands, 124  
 notional neuronal synapse, signalling, 122  
 and pain, 125–126  
 and peripheral pain processing, 126–127  
 plasticity problems, 132–133  
 supraspinal level, 130–132  
 synthesis and degradation, 124–125

Endothelial NOS (eNOS or NOS-3), 104, 105  
 Epac signaling, 22  
 Extracellular signal-regulated kinase (ERK), 21

## F

Familial episodic pain (Na<sub>v</sub>1.9), 48, 50–51  
 Fascia, 61–62  
 Fatty acid amide hydrolase (FAAH), 126–127, 133  
 Fractalkine, 216–217  
 Fragile X mental retardation protein (FMRP), 22–23  
 Functional magnetic resonance imaging (fMRI), 131, 132

## G

GABAergic neurons, 183–184  
 Gamma(γ)-aminobutyric acid (GABA)  
   amygdala, pharmacology of, 272–273  
   immunostaining for, 175  
   receptors, 215  
   spinal cord modulation of peripheral inflammation, 193–194  
 Gastrointestinal system, 245, 252  
 Glia, 211  
   activation, 214–215  
   origin and function of, 146–148  
   spinal changes (*see* Neuropathic pain)  
 Glycinergic circuits, 185–186  
 G protein-coupled receptor (GPCR), 121, 216, 222

## H

Hereditary and sensory autonomic neuropathy type IID (HSANIID), 48  
 Heterologous desensitisation, 222  
 Heteromerisation, 223–224  
 Homologous desensitisation, 222  
 Human heritable sodium channelopathy  
   familial episodic pain (Na<sub>v</sub>1.9), 50–51  
   inherited primary erythromelalgia (Na<sub>v</sub>1.7), 47–49  
   pain insensitivity (Na<sub>v</sub>1.7 and Na<sub>v</sub>1.9), 51–52  
   pain-related, 47  
   paroxysmal extreme pain disorder (Nav1.7), 49  
   selective Nav1.7 analgesics, 52–53  
   small fibre neuropathy (Na<sub>v</sub>1.7 and Na<sub>v</sub>1.8), 49–50  
 Hyperalgesic priming  
   CNS regulation of

atypical PKCs, 24–27  
 BDNF, 24–27  
 endogenous opioids, 27–29  
   μ-opioid receptor constitutive activity, 27–29  
   opioid effects, 29–30  
   surgery as priming stimulus, 29–30  
 in messenger signaling pathways, 19  
 therapeutic opportunities, 31–32  
 translational control pathways involved in, 21

## I

IL-1 receptor antagonist (IL-1ra), 214  
 Immune signalling  
   central, 214, 215, 229  
   in central nervous system, 208  
   homeostatic, 214  
   neuron–glial central, 217  
 Immuno-active agents, 196–197  
 Immunocompetent cells, in opioid pharmacodynamics, 211  
 Inducible nitric oxide synthase (iNOS) isoform, 220  
 Inducible NOS (iNOS or NOS-2), 104  
 Inflammation  
   acute cutaneous  
     pathways, 198  
     pharmacology, 197–198  
   acute joint models, 196–197  
   characteristics, 157  
   chronic itch, 295–296  
   chronic models of  
     pathways, 200  
     pharmacology, 199  
   JNK phosphorylation, 158  
   monoarthritis-kaolin/carrageenan knee, 195–196  
   nervous system effects, 8  
   and neuropathic pain, 149–150  
   PAR1, 247  
   PAR2, 248–250  
   PAR3, 250  
   PAR4, 250  
   in pathophysiologic nociceptive pain, 3  
   role of, 157  
   spinal glia mechanisms, 158  
   sympathetic terminals in, 200–201  
 Inherited primary erythromelalgia (IEM), 47–49  
 Interleukin 6 (IL-6), 22  
 Interleukin-1β (IL-1β), 156–157  
 Interleukin-1receptor (IL-1R), 156–157

- Interneurons  
 excitatory, 175–176  
 inhibitory, 174–175  
 loss, 182–183  
 reduced excitation of, 184–185
- Inotropic glutamate receptors, 266–268
- Itch  
 central sensitization  
 exact mechanisms and roles of, 294  
 mechanical hyperalgesia, 293  
 pruriceptors ongoing activity, 294  
 punctate hyperalgesia, 293  
 intensity and pattern theory  
 activated nociceptors, 291–293  
 non-histaminergic itch, 290–291  
 mechanisms for, 295–296  
 peripheral sensitization, 295  
 specificity for  
 antagonistic interaction, 288–290  
 molecular markers, 287–288
- L**
- Laterocapsular division of central nucleus of amygdala (CeLC)  
 evoked responses, 268, 271  
 excitatory synaptic transmission, 265  
 glutamatergic inputs, 266–267  
 hyperactivity of, 267  
 stimulus-evoked activity, 264  
 synaptic inhibition, 271–272
- Long-term potentiation (LTP), 7, 23, 24
- Low-threshold mechanoreceptors (LTMRs), 177
- M**
- Manganese superoxide dismutase (MnSOD), 221
- Mechanistic target of rapamycin complex 1 (mTORC1), 21
- Medication-overuse headache, 226
- Metabotropic glutamate receptors (mGluRs)  
 activation of, 270, 271  
 DCPG, 272  
 electrophysiological analysis, 270, 271  
 facilitatory effects of, 269–270  
 pattern of, 269  
 presynaptic receptors, 271  
 role of, 268  
 types, 268, 270, 271  
 ZJ43, 271
- Microglia, 210  
 cell populations, 147–148  
 monocytic/myeloid origins, 146  
 phagocytes of, 147  
 physiological conditions, 147  
 roles, 147
- Mitogen-activated protein (MAP), 202
- Mitogen-activated protein kinase (MAPK)  
 signalling pathway, 209
- Monoacylglycerol lipase (MAGL), 127, 128
- Monoarthritis-Kaolin/Carrageenan knee, 195–196
- Monocyte chemoattractant protein-1 (MCP-1), 217
- mTORC1. *See* Mechanistic target of rapamycin complex 1 (mTORC1)
- $\mu$ -opioid receptor (MOR), 27–28, 209
- Muscular mechanical hyperalgesia, 60, 61
- Musculoskeletal system, 246–247
- Myelinated nociceptors, 173
- N**
- N*-acylethanolamines (NAEs), 125
- Nacyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD), 125
- Naltrexone, 224
- Natriuretic peptide receptor A (NPR-A), 108
- Na<sub>v</sub>1.3, 46–47
- Na<sub>v</sub>1.7  
 inherited primary erythromelalgia, 47–49  
 new selective analgesics, 52–53  
 pain insensitivity, 51–52  
 paroxysmal extreme pain disorder, 49  
 rodent studies, insights from, 41, 45  
 small fibre neuropathy, 49–50
- Na<sub>v</sub>1.8  
 rodent studies, insights from, 45–46  
 small fibre neuropathy, 49–50
- Na<sub>v</sub>1.9  
 familial episodic pain, 50–51  
 pain insensitivity, 51–52  
 rodent studies, insights from, 46
- Nerve growth factor (NGF), 22  
 action mechanism  
 acute sensitization, 68–69  
 long-lasting sensitization, 69  
 mechanical stimuli sensitization, 70–71  
 cachexia pain, 67  
 cancer pain, 67  
 inflammatory pain, 62  
 musculoskeletal pain  
 cast immobilization, 65–66

- DOMS, 63–65
    - osteoarthritis models, 65–66
  - neuropathic pain, 62–63
  - nociceptive system
    - development, 59
  - nociceptor activities and axonal properties, 67–68
  - pain and mechanical/thermal hyperalgesia
    - induced
      - animals, 60
      - humans, 60–62
  - receptor, 58–59
  - and receptor trkA, 9–10
  - therapeutic perspective, 71
  - visceral painful conditions, 66
- Nervous system, 244–245
- Neuroglia, 146
- Neuronal NOS (nNOS or NOS-1), 104, 105
- Neuropathic pain
  - animal models of, 180–181
  - astrocytic responses, to injury, 152
  - cathepsin S, 153–154
  - CX3CL1/R1, 153–154
  - definition, 3
  - IL-1 $\beta$ , 156–157
  - IL-1R, 156–157
  - inflammatory pain and, 149–150
  - microglial responses to injury, 150–151
  - neuronal mechanisms of, 5–8
  - PAR1, 251
  - PAR2, 251, 252
  - PAR3 and PAR4, 252
  - possible mechanisms, reduced inhibition of
    - GABAergic neurons, 183–184
    - glycinergic circuits role, 185–186
    - inhibitory interneurons excitation, 184–185
    - inhibitory interneurons loss, 182–183
    - inhibitory transmission effectiveness, 185
  - process of, 6
  - reduced inhibitory synaptic transmission in, 181
  - TNF, 154–155
  - TNFR, 154–155
- Neuropathy, 295–296
- Neuropeptide
  - CGRP, 274–275
  - CRF, 275–277
  - NPS, 277–278
- Neuropeptide S (NPS), 277–278
- NGF. *See* Nerve growth factor (NGF)
- NG-nitro-L-arginine (L-NOARG), 220
- NG-nitro-L-arginine methyl ester (L-NAME), 220
- Nitric oxide (NO), 220
- Nitric oxide (NO)-mediated pain processing
  - in dorsal root ganglia, 104–105
  - downstream mechanisms of
    - cGMP signaling, 108–110
    - NO-GC activation, 107–108
    - peroxynitrite formation, 110–111
    - S-nitrosylation, 110
  - pro- and antinociceptive functions of, 105–106
  - in spinal cord, 104–105
- Nitric oxide(NO)-sensitive guanylyl cyclase (NO-GC), 107–108
- Nitric oxide synthase (NOS), 220
  - inhibitors, 105–106
  - isoforms, 104
- N-methyl-D-aspartate (NMDA) receptors, 28
- Nociceptive system
  - acute sensitization
    - direct phosphorylation by TrkA, 68–69
    - indirect action of, 69
    - membrane trafficking of TRPV1, 69
    - sympathetic nerve involvement, 69
  - central, 4
  - descending system, 5
  - development, 59
  - long-lasting sensitization to heat, 69
  - mechanical stimuli sensitization
    - mechanical hyperalgesia, 70
    - mechanical hypersensitivity, 70
    - TrkA, 70–71
  - molecular mechanisms of, 8–11
  - peripheral, 4
  - thalamocortical system, 4
- Nociceptor priming
  - animal models, 18
  - chronic pain conditions, 18
  - hyperalgesic priming (*see* Hyperalgesic priming)
  - local translation, key mediator of, 20
    - CPEB, 23
    - epac signaling, 22
    - experimental paradigm, 23
    - FMRP, 23
    - PKC $\epsilon$ -induced priming, 24
    - in sensory neurons, 22
    - translation, 21
  - naïve rodents, 18
  - PKC $\epsilon$ , crucial mechanism of, 19–20
  - preclinical models, 16
  - prostaglandins, 18

- Non-neuronal cell intracellular signalling, 208, 209
- Non-neuronal central immune cells, 209  
 astrocytes, 210–211  
 central immune synergy, 211  
 microglia, 210
- O**
- Offset analgesia, 91–92
- Opioid-induced cytokine signalling, 225–226
- Opioid-induced initiation  
 analgesia opposition  
 ATP, 219–220  
 chemokines, 216–217  
 cholecystokinin, 217–219  
 cytokines, 213–215  
 nitric oxide, 220  
 potentiating/unmasking, 214  
 proinflammatory cytokine-mediated  
 neuronal excitation, 215–216  
 sphingomyelins, 220–222  
 gonadal hormone contribution, 228
- Opioid-overuse headache, 225–226
- Opioids, 208  
 pharmacodynamics, 211  
 tolerance, 208, 209, 218
- P**
- Pain insensitivity (Nav1.7 and Nav1.9), 51–52
- Paroxysmal extreme pain disorder (PEPD), 48, 49
- Pathophysiologic nociceptive pain  
 definition, 3
- Periaqueductal grey matter (PAG), 130–131, 217
- Peripheral nerve injury. *See* Neuropathic pain
- Peripheral nervous system (PNS)  
 CB<sub>1</sub> receptor, 123  
 targeting, 31
- Peripheral nociceptive system, 4
- Peripheral pain processing, EC system, 126–127
- Peripheral sensitization  
 molecular mechanisms of, 5–6  
 pain, 295
- Peroxynitrite, 221
- Phosphoinositide 3-kinases (PI3Ks), 249
- Physiologic nociceptive pain, 3
- Postherpetic neuralgia (PHN), 82
- Primary afferent axons, 172–173
- Primary afferent depolarization (PAD), 193–194
- Proinflammatory cytokine-mediated  
 neuronal excitation, 215–216
- Proinflammatory cytokines, 214
- Projection neurons  
 in anterior lateral tract (ALT), 173, 176–177  
 selective innervation of, 178
- Proteases  
 categories, 240  
 proteolytic properties, 240
- Proteinase-activated receptor (PAR), 10  
 activating peptides and antagonists, 241  
 activation, 240–242  
 cardiovascular system, 243–244  
 cleaving enzymes, 241  
 definition, 240  
 desensitisation mechanisms, 243  
 drug target for pain, 253–254  
 gastrointestinal system, 245  
 and inflammatory pain, 247–250  
 musculoskeletal system, 246–247  
 nervous system, 244–245  
 neuropathic pain, 250–252  
 signalling  
 PAR1, 242  
 PAR2, 243  
 PAR3 and PAR4, 243
- Protein kinase A (PKA), 19
- Protein kinase G (PKG), 108
- Protein kinase M zeta (PKM $\zeta$ ), 24
- Provoked central sensitization, 86, 87
- Punctate hyperalgesia, 293
- P2X4 receptors, 219
- Q**
- Quantitative sensory testing (QST)  
 assessment methods, 84  
 descending pain modulation, 90–91  
 different protocols, 84  
 localized *vs.* general hyperalgesia problem, 85–86  
 offset analgesia, 91–92  
 provoked facilitation, 86, 87  
 referred pain, 92–93  
 reflex receptive fields, 89–90  
 spatial summation, 89  
 temporal summation and aftersensation, 86–88
- R**
- Receptor activity-modifying protein  
 1 (RAMP1), 274
- Receptor binding  
 non-stereoselective, 212–213
- Receptor crosstalk, molecular mechanisms of, 222–225

- Referred pain, 92–93
- Reflex receptive fields, 89–90
- Rheumatoid arthritis (RA) pain  
analgesic effect of, 160  
characteristics, 158  
clinical signs of, 158  
poly-arthritic rodent models, 159  
spinal microglia role, 160  
treatment of, 159
- Rhizotomy, 192–193
- Rostral ventromedial medulla (RVM)  
and cholecystokinin, 218  
excitatory projections to, 131  
microinjection, of cannabinoid agonists,  
130
- S**
- SCN9A* gene, 47, 48, 50
- SCN10A* gene, 47
- SCN11A* gene, 47, 50
- Seven-transmembrane (7TM) receptors, 222
- Small fibre neuropathy (SFN), 49–50
- S-nitrosylation, 110
- Sodium channels  
Na<sub>v</sub>1.3, 46–47 (*see also* Nav1.3)  
Na<sub>v</sub>1.7, 41, 45 (*see also* Nav1.7)  
Na<sub>v</sub>1.8, 45–46 (*see also* Nav1.8)  
Na<sub>v</sub>1.9, 46 (*see also* Nav1.9)  
Na<sub>v</sub> transgenic mice studies, 41–44
- Soluble guanylyl cyclase (sGC), 107
- Spared nerve injury (SNI), 181
- Spatial summation, 89
- Sphingomyelins, 220–222
- Sphingosine, 220
- Sphingosine kinases (SphK) 1 and 2,  
220–221
- Spinal cord  
excitatory synaptic transmission in, 10  
mechanisms, 10–11  
nociceptive neurons in, 4
- Spinal cord inhibitory mechanisms  
descending pathways, 176  
neurons and circuits  
interneurons, 174–176  
normal function of inhibitory  
mechanisms, 179–180  
presynaptic inhibitory, 179  
primary afferents, 172–173  
projection neurons, 173–174  
selective innervation of, 178  
synaptic connections, 176, 177
- neuropathic pain  
animal models, 180–181  
possible mechanisms, 181–186  
reduced inhibitory synaptic  
transmission in, 181
- Spinal cord modulation of peripheral  
inflammation  
acute cutaneous inflammation, 197–198  
acute inflammatory models, 195–196  
chronic models of, 199–200  
dorsal root reflex, 193–194  
joint inflammation, 196–197  
rhizotomy, 192–193  
spinovagal circuitry, 201–202  
sympathetic effects on, 200–201
- Spinal endocannabinoid system. *See*  
Endocannabinoid (EC) system
- Spinal glia. *See also* Neuropathic pain  
during inflammatory pain, 157–158  
during rheumatoid arthritis pain, 158–160
- Spinal immune cell function, 130
- Spinal nerve ligation (SNL), 181
- Spinal sensitization, 7
- Spinovagal circuitry, 201–202
- Stereoselective receptor binding, 212–213
- Superoxide dismutase (SOD), 221
- Sympathectomy, 200, 201
- T**
- Temporal summation and aftersensation,  
86–88
- Terminal deoxynucleotidyl  
transferasemediatedbiotinylated  
UTP nick end labelling (TUNEL),  
182
- Thalamocortical system, nociceptive neurons  
in, 4–5
- Toll-like receptor-4 (TLR4)  
LPS activation, 222  
medication-overuse headache, 226  
in non-stereoselective binding, 213  
opioids and, 228
- Toll-like receptors (TLRs), 226
- Tropomyosin-related kinase A (TrkA)  
direct phosphorylation by, 68–69  
mechanical stimuli sensitization, 70–71  
membrane trafficking of TRPV1 by, 69
- Tumor necrosis factor (TNF)  
spinal cord, in neuropathic and  
inflammatory pain, 154–155  
spinal pretreatment with, 196
- V**
- Voltage-gated sodium channels (VGSCs)  
alpha subunit, primary structure of, 40, 41  
mammalian, 40